Overview

All information and news about Medincell stock (Euronext Paris: MEDCL)

Medincell share price

21.76€

-0.58 / -2.6%

2026-09-18 17:35 (Paris)

Data provided by Euronext, in real time.

See stock quote, chart & historical on Euronext.com

Listed on

Euronext Paris /
B Compartment

ISIN code / Ticker

FR0004065605 /
MEDCL

Number of shares

35,907,508
(March 31, 2026)

Liquidity Provider

Rothschild Martin Maurel

Analyst coverage

Medincell is followed by the analysts listed. Please note that any opinions, estimates, or forecasts regarding Medincell’s performance made by these analysts are theirs alone and do not represent opinions, forecasts, or predictions of Medincell or its management. Medincell does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions, or recommendations.

Company

Analyst

Contact

Leerink Partners

Marc Goodman

Evercore

Michael DiFiore

Truist Securities

Les Sulewski

H.C. Wainwright & Co.

Raghuram Selvaraju

Jefferies

Shan Hama

Stifel

Damien Choplain

Degroof Petercam

David Seynnaeve

ODDO BHF

Martial Descoutures

Kepler Chevreux

Nicolas Pauillac

Portzamparc

Mohamed Kaabouni

TP ICAP

Jean-Pierre Tabart

Documentation

September 2026

Investor Presentation

2025

CSR Report

Latest news

Medincell to Participate in Upcoming Investor Conferences
September 9, 2026

Medincell to Participate in Upcoming Investor Conferences

Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting
September 8, 2026

Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting

Medincell appoints Edna Venneker, MD, as Chief Medical Officer
September 1, 2026

Medincell appoints Edna Venneker, MD, as Chief Medical Officer

Medincell’s Dr Grace Kim to Participate in Piper Sandler CNS Symposium
August 11, 2026

Medincell’s Dr Grace Kim to Participate in Piper Sandler CNS Symposium

UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook
July 29, 2026

UZEDY®: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook

Investors contacts

Medincell

David Heuzé

Head of Corporate and Financial Communications, and ESG

Medincell

Grace Kim

Head of US Financial Strategy & IR

Investor relations

Louis-Victor Delouvrier
& Alban Dufumier

Newcap

Media

Nicolas Merigeau

Newcap